Improved cardiac function in a patient with hypereosinophilic syndrome treated with imatinib

被引：3

作者：

Musial, J ^{[1
]}

Brzezinska-Kolarz, B ^{[1
]}

Sanak, M ^{[1
]}

Szczeklik, A ^{[1
]}

机构：

[1] Jagiellonian Univ, Dept Med, PL-31066 Krakow, Poland

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2005年 / 75卷 / 01期

关键词：

D O I：

10.1111/j.1600-0609.2005.00490.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：87 / 88

页数：2

共 7 条

[1] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[2] Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome [J].

Cortes, J ;

Ault, P ;

Koller, C ;

Thomas, D ;

Ferrajoli, A ;

Wierda, W ;

Rios, MB ;

Letvak, L ;

Kaled, ES ;

Kantarjian, H .

BLOOD, 2003, 101 (12) :4714-4716

[3] Treatment of hypereosinophilic syndrome with imatinib mesilate [J].

Gleich, GJ ;

Leiferman, KM ;

Pardanani, A ;

Tefferi, A ;

Butterfield, JH .

LANCET, 2002, 359 (9317) :1577-1578

[4] The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia:: implications for diagnosis, classification, and management [J].

Gotlib, J ;

Cools, J ;

Malone, JM ;

Schrier, SL ;

Gilliland, DG ;

Coutré, SE .

BLOOD, 2004, 103 (08) :2879-2891

[5] FIP1L1-PDGFRA fusion:: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia [J].

Pardanani, A ;

Brockman, SR ;

Paternoster, SF ;

Flynn, HC ;

Ketterling, RP ;

Lasho, TL ;

Ho, CL ;

Li, CY ;

Dewald, GW ;

Tefferi, A .

BLOOD, 2004, 104 (10) :3038-3045

[6] Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders [J].

Pardanani, A ;

Tefferi, A .

BLOOD, 2004, 104 (07) :1931-1939

[7] Recent advances in pathogenesis and management of hypereosinophilic syndromes [J].

Roufosse, F ;

Cogan, E ;

Goldman, M .

ALLERGY, 2004, 59 (07) :673-689

← 1 →